$POST

2 Profitable Stocks with Exciting Potential and 1 We Find Risky

Post (POST) is flagged for potential decline due to projected sales drop, low gross margin, and poor capital returns. Terex (TEX) and Amgen (AMGN) are highlighted for growth potential, with TEX showing strong revenue growth and AMGN demonstrating high returns on capital. POST trades at 10.4x forward P/E, TEX at 9.8x, and AMGN at 18x.

Original reporting
Published Oct 1, 2026, 4:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 8:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
2 Profitable Stocks with Exciting Potential and 1 We Find Risky — source image
Decision brief

The 30-second read

$POSTBearishLow
01

Why it matters

The piece provides no fresh corporate events; it merely restates existing metrics and forward‑looking statements.

02

Market read

Low relevance; the article is a generic stock‑watch list without new data.

03

What to watch

Terex's growth could be cyclical; Amgen faces patent expiration risks not discussed.

Relevance 4/10Novelty 2/10Timing: none

Background

A promotional article from StockStory offering opinionated stock picks without new corporate disclosures.

Company-level read

Ticker impact

$POSTBearishMedium confidence
Context

The article recommends selling Post (POST) citing projected 5.9% sales decline and low margins.

Expected impact

likely downside as investors reassess growth prospects

Evidence & confidence

The piece flags a sales contraction and margin weakness, which could prompt sell‑offs.

$TEXBullishMedium confidence
Context

The article flags Terex (TEX) as a watch with projected 27.6% revenue growth and rising free cash flow.

Expected impact

possible rally if growth expectations are priced in

Evidence & confidence

High projected revenue growth and cash flow improvements suggest favorable fundamentals.

$AMGNBullishMedium confidence
Context

The article highlights Amgen (AMGN) as a buy candidate, noting its large revenue base and strong free cash flow.

Expected impact

could see buying pressure if investors act on the favorable fundamentals

Evidence & confidence

Emphasis on scale and cash flow may encourage investors to add positions.

Market effects

Highlights profitability concerns in packaged foods and growth prospects in industrial equipment and biotech.

U.S. equities may see modest sector rotation based on the mixed outlooks.

Limited; the commentary is U.S.-focused and does not affect broader macro trends.

Counterpoint

Post's margins may improve if it pivots to higher‑margin product lines, contrary to the sell recommendation.

Key entities

  • Post Holdings

    Packaged food company recommended for sale.

  • Terex Corporation

    Industrial equipment maker highlighted as a watch.

  • Amgen Inc.

    Biotech firm presented as a buy.

Related articles

$ABBVMed

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

The Trump administration selected 10 drugmakers, including AbbVie, Amgen, Pfizer, and GSK, for a 340B rebate pilot program starting January 1. The program tests a rebate model for 21 discounted drugs under the 340B program. The HRSA oversees the initiative, aiming to address compliance proactively. The program is contentious, with pharmaceutical companies and hospitals disputing its impact.

$NVSHighAI 8/10

Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer

Novartis' ianalumab and Amgen's dazodalibep met primary endpoints in late-stage trials for Sjögren disease, with Novartis receiving FDA breakthrough therapy designation. RemeGen's telitacicept was approved in China. Sjögren disease patients incur higher healthcare costs, and current treatments focus on symptom relief.

$AMGNMed

Drugmakers Turn to Proteomics to Map How Medicines Work

Drugmakers are increasingly using proteomics to study protein-level pathways of drug effects. Amgen, AstraZeneca, Johnson & Johnson, and MSD are involved in a UK Biobank project. In Korea, Bertis' proteomics tech was used in Hanmi Pharmaceutical's obesity drug research. The global proteomics market is expected to grow to $97.7B by 2033, per Grand View Research.